摘要
目的调查鲍氏不动杆菌的临床分布及耐药性,为临床治疗鲍氏不动杆菌的感染提供依据。方法收集2012年7月-2014年6月从住院患者标本中分离获得的鲍氏不动杆菌及相应资料,对分离株进行鉴定及药敏。结果 2012年7月-2014年6月共分离626株鲍氏不动杆菌,主要分布在ICU、神经外科、心胸外科、呼吸内科、外科麻醉重症复苏室,分别占36.1%、15.5%、8.6%、6.9%、6.5%。来源标本以痰液为主,占80.0%。鲍氏不动杆菌对阿米卡星、亚胺培南、美罗培南、头孢哌酮/舒巴坦的耐药率相对较低分别为44.4%、30.4%、30.7%、31.3%,其他抗菌药物的耐药率均>50.0%,其中对氨苄西林、头孢替坦、氨曲南的耐药率分别达到96.2%、93.3%、89.1%。结论鲍氏不动杆菌耐药现象严重,阿米卡星、亚胺培南、美罗培南、头孢哌酮/舒巴坦可作为治疗鲍氏不动杆菌感染治疗的首选药物。
Objective To investigate the clinical distribution and antibiotic resistance of Acinetobacter baumannii in order to provide guidance for clinical treatment of Acinetobacter baumannii infections. Methods The Acinetobacter baumannii strains i- solated from specimens of inpatients from July 2012 to June 2014 and their data were collected. The identification and drug sus- ceptibility testing were carried out for these isolates. Results A total of 626 strains of Acinetobacter baumannii were obtained, which were mainly from ICU （ 36.1% ）, departments of neurosurgery （ 15.5% ）, cardiothoracic surgery （ 8.6% ）, respiratory medicine （6.9%） and post anesthesia care unit（6.5 % ）. Most of these strains were isolated from sputum specimens （80.0%）. The drug resistance rates of these isolates were relatively low to amikacin （ 44. 4% ）, imipenem （ 30. 4% ）, meropenem （30.7%） and cefoperazone - sulbactam （31.3%） while more than 50% to the other antibiotics, reaching up to 96.2%, 93.3% and 89.1%, respectively, to ampicillin, cefotetan and aztreonam. Conclusion Drug resistance of Acinetobacter bau- mannii is a serious problem; amikacin, imipenem, meropenem and cefoperazone - sulbactam should be considered to be first - choice drugs for the treatment of Acinetobacter baumannii infections.
出处
《中国卫生检验杂志》
CAS
2016年第14期2109-2111,共3页
Chinese Journal of Health Laboratory Technology
基金
广西壮族自治区卫生厅计划课题(Z2013521)
关键词
鲍氏不动杆菌
临床分布
耐药性
Acinetobacter baumannii
Clinical distribution
Drug resistance
